Reovirus Appears to Have a Redemptive Quality - The Ability to Kill Cancer
Published : 2010-10-20
Author : Georgetown University Medical Center
Synopsis: Reovirus that can cause coughing and mild diarrhea appears to have a major redemptive quality - the ability to kill cancer.
Main DigestA common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer.
Harnessing that power, researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, are conducting a clinical trial to see if the virus can target and kill certain tumor types.
By the age of five, most people have been exposed to the virus, called reovirus. For some, it can trigger brief episodes of coughing or diarrhea while many other don't develop any symptoms. The body simply overpowers the virus. But what scientists have discovered is that the virus grows like gangbusters inside tumor cells with a specific malfunction that leads to tumor growth. That finding led researchers to ask: Is it possible to use the virus as a treatment
At Lombardi, researchers are collaborating with other institutions to look for an answer by conducting a phase II clinical trial for people with advanced or recurrent non-small cell lung cancer with a specific tumor profile.
"With reovirus, we're able to accentuate the positive and attenuate the negative," says the study's lead investigator at Lombardi, Deepa Subramaniam, MD, interim-chief of the Thoracic Medical Oncology Program. In other words, researchers have genetically altered the virus so that it won't replicate in a healthy cell (attenuated), which is what makes a person sick. "What's left is a virus in search of a host, and reovirus loves the environment inside a specific kind of cancer cell," explains Subramaniam.
That specific kind of cancer cell is one with malfunctioning machinery called KRAS or EGFR mutation.
"These mutations leave the cancer vulnerable to a viral take-over. Once it's in, the reovirus exploits the cell's machinery to drive its own replication. As a result, the cell is filled with virus particles causing it to literally explode."
Volunteers in the clinical trial will receive reovirus (REOLYSIN®) in addition to paclitaxel and carboplatin. The physicians will watch to see if the cancer shrinks while also seeing if this combination of drugs causes serious side effects.
"This is a subset of cancer where we haven't had many successes in terms of finding drugs that extend life after diagnosis," says Subramaniam. "This trial represents an attempt to seek and destroy cancer by choosing a treatment based on specific tumor characteristics. Preliminary data from the study should come quickly."
Researchers are also studying the effect of reovirus in other cancer types.
Patients interested in learning about this or any other clinical trial should call 202-444-4000.
This study is sponsored by Oncolytics Biotech Inc., maker of REOLYSIN. Subramaniam reports no potential financial interest.
About Lombardi Comprehensive Cancer Center - The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 41 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to lombardi.georgetown.edu.
About Georgetown University Medical Center - Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis - or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.
You're reading Disabled World. See our homepage for informative disability news, reviews, sports, stories and how-tos. You can also connect with us on social media such as Twitter and Facebook or learn more about Disabled World on our about us page.
Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information. Please report outdated or inaccurate information to us.
Cite Page: Journal: Disabled World. Language: English (U.S.). Author: Georgetown University Medical Center. Electronic Publication Date: 2010-10-20. Title: Reovirus Appears to Have a Redemptive Quality - The Ability to Kill Cancer, Source: <a href=https://www.disabled-world.com/medical/clinical-trials/reovirus-cancer.php>Reovirus Appears to Have a Redemptive Quality - The Ability to Kill Cancer</a>. Retrieved 2021-06-19, from https://www.disabled-world.com/medical/clinical-trials/reovirus-cancer.php - Reference: DW#340-5908.